




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A01N 37/18, 57/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/18230 (43) International Publication Date: 6 April 2000 (06.04.00)</p>
<p>(21) International Application Number: PCT/US99/22199 (22) International Filing Date: 24 September 1999 (24.09.99) (30) Priority Data: 09/161,804 28 September 1998 (28.09.98) US (71) Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK [US/US]; P.O. Box 9, Albany, NY 12201-0009 (US). (72) Inventors: RAMAMURTHY, Nungavarm, S.; 10 Lynam Court, Smithtown, NY 11787 (US). GOLUB, Lorne, M.; 29 Whitney Gate, Smithtown, NY 11787 (US). SORSA, Timo, A.; Lounaisvayla 17, FIN-00200 Helsinki (FI). TERONEN, Olli, P.; Kylanvanhimmankja 9B, FIN-00640 Helsinki (FI). SALO, Tuula, A.; Fyysikontie 8, FIN-90570 Oulu (FI). (74) Agent: BARON, Ronald, J.; Hoffmann & Baron, LLP, 6900 Jericho Turnpike, Syosset, NY 11791 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: COMBINATION OF BISPHOSPHONATE AND TETRACYCLINE



(57) Abstract

Tissue-destructive conditions related to excess proteinase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts. The effectiveness of such compositions can be demonstrated in standard tests, for example by measuring tooth mobility.

Dr. Reddy's Laboratories, Ltd., et al.
v.
Galderma Laboratories, Inc.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macédonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMBINATION OF BISPHOSPHONATE AND TETRACYCLINE

This invention was made with government support under R37DE03987 awarded by the National Institute of Dental Research (NIH). The government has certain rights in the invention.

The invention relates to a combination of tetracyclines and bisphosphonates which act synergistically to inhibit, reduce, down-regulate and/or prevent degradation of connective tissue, basement membrane as well as other factors in subjects susceptible to this type of tissue degradation.

BACKGROUND OF THE INVENTION

Proteolytic activity is responsible for damage to connective tissues and basement membranes as a complication of the inflammatory and/or immune response and other disease processes, such as cancer cell invasion and metastasis. The inflammatory response contributes, for example, to the pathological changes in a number of acute and chronic processes involving diverse organs and tissues such as the lungs, bone, heart, joints, skin and periodontium, etc.

The proteinases involved in these responses or disease processes include matrix metalloproteinase (MMP's), MMP-like proteinases and related proteinases, serine proteinases and other proteinases. The MMP's are zinc and calcium-dependent for hydrolytic cleavage of substrate proteins and are secreted or released by a variety of host cells (e.g., polymorphonuclear neutrophils (PMN's), macrophages, bone cells, epithelium and fibroblasts). Certain other genetically distinct MMP's called membrane-type MMP's (MT-MMP's) are cell membrane-bound; others are secreted into the extracellular matrix (ECM). With serine proteinases, the amino acid serine acts as a nucleophile for hydrolytic cleavage of substrate protein. Serine proteinases are released, e.g., by triggered leukocytes, more specifically by the azurophilic granules of PMN's, and other cells including malignant tumor cells.

Several studies have shown that the expression and activities of MMPs are pathologically elevated over the body's endogenous anti-proteinase shield in a variety of diseases such as cancer metastasis, rheumatoid arthritis, multiple sclerosis, periodontitis, osteoporosis, osteosarcoma, osteomyelitis, bronchiectasis, chronic pulmonary obstructive disease, skin and eye diseases. Proteolytic enzymes, especially MMPs, are believed to contribute to the tissue destruction damage associated with these diseases.

Some metalloproteinases (MMP's) and their association with diseases are discussed by M.E. Ryan, et al., *Curr. Op. Rheum.*, 1996, 8:238-247. More than twenty MMP's have been identified and the number is growing. These include Interstitial Collagenases MMP-1 (fibroblast-type), MMP-8 (polymorphonuclear leukocyte - PMNL- type or collagenase-2), MMP-13 (collagenase-3); Gelatinases MMP-2 (72-kD gelatinase A) and MMP-9 (92-kD gelatinase B); Stromelysins MMP-3 (stromelysin - 1), MMP-10 (stromelysin -2), and MMP-7 (matrilysin or putative metalloproteinase (PUMP) -1); Membrane Type (MT-MMP's), MMP-14 (MT₁-MMP), MMP-15 (MT₂-MMP), MMP-16 (MT₃-MMP); others are, for example, MMP-11 (stromelysin -3), MMP-12 (macrophage metalloelastase) and MMP-20. Enamelysin (MMP-20) is described by Llano et al., *Biochem.* 1997, 36:15101-15108, and can also be expressed by human cancer cells such as squamous carcinoma cells of the human tongue indicating its potential contribution to cancer progression and invasion (Salo et al., *J. Dent. Res.* 1998, 77:829, Abstr. No. 1978). Related proteinases include TACE's and ADAM's fertilin or meltrin (metalloproteinase/disintegrin).

MMP's, MMP-like and related proteinases such as TACE's, ADAM's, etc., are involved in processing and modification of molecular phenomena such as tissue remodeling (Birkedal-Hansen, *Current Opin. Cell Biol.* 1995, 7:728-735; JF Woessner, Jr., *FASEB J.* 1991, 5:2145-2154), cytokine actions (S. Chandler et al., *J. Neuroimmunol.* 1997, 72:155-161), cell-cell fusion (RH van Huijsduijen, *Gene* 1998, 206:273-282; Huovila et al., *Curr. Opin. Cell Biol.* 1996, 8:692-699; Yagami-Hiromasa et al., *Nature* 1995, 377:662-656), angiogenesis, growth factor actions,

integrin and other adhesion factors and their receptor processings. See also, A.C. Perry et al., *Biochem. Biophys Acta* 1994, 1207:134-137. The ADAM enzymes are membrane proteins with A Disintegrin and Metalloproteinase Domain (Wolfsberg et al., *Dev. Biol.* 1995, 169:378-383). TACE is tumor necrosis factor converting
5 enzyme.

MMP-like proteinases and related proteinases are metalloproteinases distinct from classic MMP's and can be involved in cellular processing of pro-TNF alpha (Tumor Necrosis Factor), cellular shedding of cytokine receptors, adhesion molecules, etc. as described by S. Chandler et al., *J. Neuroimmunol.* 1997, 72:155-161. MMP's
10 and MMP-like and related enzymes, e.g., ADAM's, TACE's, etc., also mediate the release of TNF alpha (Watanabe et al., *Eur. J. Biochem.* 1998, 253: 576-582) and are involved in membrane-bound processing of TNF alpha by monocytes induced by bacterial-virulence factors. This event is mediated by membrane-bound metalloproteinases. Shapira et al., *J. Period. Res.* 1997, 32:183-185.

15 There is extensive evidence for the association between proteinases and a large number of disease processes. Microbial proteinases can act in concert with host proteinases in the promotion of tissue destruction as seen in periodontium (Sorsa et al., *Infect. Immun.* 1992, 60: 4491-4495). Recent studies indicate that a serine protease, i.e., elastase, may play a role in connective tissue breakdown and tissue invasion in the
20 Dunning rat model of cancer invasion and metastases (prostate cancer) (Lowe and Isaacs, *Cancer Res.* 1984, 44:744-52). Also involved in initiating the proteinase cascade that mediates tumor invasion and metastasis are trypsin and chymotrypsin-like activity (Sorsa et al., *J. Biol. Chem.* 1997, 272:21067-21074). Serine proteinase is
25 expressed in human cancers such as ovarian carcinoma and cholangiosarcoma (Sorsa et al., *J. Biol. Chem.* 1997, 272:21067-21074).

The role of MMP's has been well-established in a great many disease states, e.g., tumor invasion and metastasis (Stetler-Stevenson et al., *Annu. Rev. Cell Biol.* 1993, 9:541-73; Tryggvason et al., *Biochim. Biophys. Acta* 1987, 907:191-217) and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.